Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

WVE - Wave Life Sciences Ltd. So'nggi Yangiliklar | Finranks

Home

WVE

W

Wave Life Sciences Ltd. (WVE)

NGM – Real vaqt narxi. Valyuta: USD

6.37

+0.17 (2.66%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

6.40

+0.04 (0.55%)

Bozordan keyin: Mar 27, 2026, 7:56 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript

WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks

WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks

Wave Life Sciences stock plunges after interim phase I data for WVE-007 showed modest fat reduction at higher dose, despite some sustained benefits.

Wave Life Sciences Slips as Obesity Data Fails to Convince

Wave Life Sciences Slips as Obesity Data Fails to Convince

Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets following updated Phase 1 INLIGHT trial data for WVE-007, the company's obesity candidate.

Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints

Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints

Expand NASDAQ: WVE Wave Life Sciences Today's Change (-49.84%) $-6.13 Current Price $6.17 Key Data Points Market Cap $2.3B Day's Range $5.04 - $6.48 52wk Range $5.04 - $21.73 Volume 1.5M Avg Vol 3.3M Gross Margin 79.28% Wave Life Sciences (WVE 49.84%), developer of RNA medicines for rare genetic diseases, closed Thursday at $6.20, down 49.59% for the session. The stock sank after disappointing higher-dose WVE-007 obesity data underperformed the lower dose.

Wave Life Sciences shares plummet on weight loss therapy update

Wave Life Sciences shares plummet on weight loss therapy update

Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007, its investigational INHBE GalNAc-siRNA therapy, despite results showing improvements in body composition and continued safety and tolerability. The Phase 1 INLIGHT trial reported that a single 240 mg dose of WVE-007 produced placebo-adjusted reductions of 14.3% in visceral fat, 5% in total fat, a 2% increase in lean mass, a 3.3% reduction in waist circumference, and a 0.9% reduction in body weight after six months.

Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data?

Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data?

At the six-month follow-up, a single 240 mg dose of WVE-007 demonstrated significant placebo-adjusted reductions in visceral fat by 14%, total fat by 5%, and waist circumference by 3%, while stabilizing lean mass with a 2% increase.

WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Wave Life Sciences Ltd. (NASDAQ: WVE). The investigation focuses on Wave Life Sciences' executive officers and whether investor losses may be recovered under federal securities laws.

Videolar

No Data

There is no data to display

Press-relizlar

WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Wave Life Sciences Ltd. (NASDAQ: WVE). The investigation focuses on Wave Life Sciences' executive officers and whether investor losses may be recovered under federal securities laws.

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass